Form 4: BioXcel Therapeutics Director June Bray Acquires 17,000 Stock Options

Director June Bray acquired 17,000 stock options in BioXcel Therapeutics on June 10, 2024.

Summary

• On June 10, 2024, June Bray, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options.
• The options have an exercise price of $1.44.
• The options vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting, contingent on continued service as a non-employee director.
• The options expire on June 10, 2034.
• Following the transaction, June Bray directly owns 17,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence but doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, acquisition, BTAI, BioXcel Therapeutics, Form 4, June Bray